Xconomy

From Psylin Neurosciences—-Amylin’s Pysch-Drug Offspring—Nearing First Clinical Trial:

Psylin Neurosciences logo
Psylin Neurosciences logo

Psylin Neurosciences is developing peptide-based drugs for psychological disorders.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.